Halozyme Therapeutics Inc (HALO)

Fixed asset turnover

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Revenue (ttm)	US$ in thousands	1,015,324	947,355	873,304	862,989	829,253	780,710	773,653	704,980	660,116	580,623	487,477	471,567	443,310	463,010	412,496	331,262	267,594	199,556	180,470	164,397
Property, plant and equipment	US$ in thousands	—	—	—	—	—	74,669	74,559	—	75,570	36,674	37,091	8,513	8,794	9,588	10,132	10,366	10,593	10,252	11,169	11,752
Fixed asset turnover		—	—	—	—	—	10.46	10.38	—	8.74	15.83	13.14	55.39	50.41	48.29	40.71	31.96	25.26	19.47	16.16	13.99

December 31, 2024 calculation

Fixed asset turnover = Revenue (ttm) ÷ Property, plant and equipment
= $1,015,324K ÷ $—K
= —

Fixed asset turnover is a financial ratio that measures a company's efficiency in generating sales revenue from its investment in fixed assets. In the case of Halozyme Therapeutics Inc, the fixed asset turnover ratio has exhibited significant fluctuations over the years.

From March 31, 2020, to December 31, 2021, the fixed asset turnover ratio showed a consistent increasing trend, indicating that Halozyme was able to generate more sales revenue relative to its investment in fixed assets during this period. This trend suggests improved efficiency in utilizing fixed assets to generate revenue.

However, from June 30, 2022, to December 31, 2023, the fixed asset turnover ratio experienced a sharp decline, indicating a decrease in the company's ability to generate sales from its fixed asset base. This could be due to various reasons such as underutilization of assets, lower sales volume, or inefficient asset management.

The ratio remained low or became unavailable in the later periods (March 31, 2024, and onwards), which could imply challenges in relating sales revenue to the value of fixed assets owned by the company during those periods.

Overall, fluctuations in the fixed asset turnover ratio for Halozyme Therapeutics Inc reflect changing efficiencies in utilizing fixed assets to drive sales revenue and may warrant further investigation into the company's operational performance and asset management strategies during those periods.